Purpose: Although associated with an overall favorable survival rate, the heterogeneity of
non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and …

Urothelial carcinoma of the urinary bladder is a heterogeneous disease with multiple
possible treatment modalities and a wide spectrum of clinical outcome. Treatment decisions …

Purpose: The purpose of this American Urological Association (AUA)/Society of Urologic
Oncology (SUO) guideline amendment is to provide a useful reference on the effective …

CONTEXT: Pathology standards for the diagnosis of bladder cancer (BCa) have recently
evolved to better reflect patient diagnosis and clinical outcomes. OBJECTIVE: To update …

Outcome prediction in patients with bladder cancer has improved through the development
of nomograms and predictive models. However, integration of further characteristics such as …

Study Type–Therapy (case series) Level of Evidence 4 What's known on the subject? and
What does the study add? The reported discordance between staging on transurethral …

Methods We update the previously published 2009 Canadian guidelines on the
management of NMIBC, emphasizing intravesical therapy. 18 We conducted a …

CONTEXT: Intravesical bacillus Calmette-Guérin (BCG) is a standard conservative treatment
for patients with high-risk non–muscle-invasive bladder cancer (NMIBC). Many patients will …

BACKGROUND Risk stratification is a major challenge in bladder cancer (BC), and a
biomarker is needed. Multiple studies have reported the neutrophil‐to‐lymphocyte ratio …

Objectives This study aimed to elucidate the relationship between lymphovascular invasion
(LVI) at transurethral resection of bladder tumor (TURBT) and the risk of pathologic …